2023
Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis?
Woodard G, Cho C, Chen L. Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis? Annals Of Surgical Oncology 2023, 31: 25-27. PMID: 37899411, DOI: 10.1245/s10434-023-14388-1.Peer-Reviewed Original Research
2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance indexMesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley‐Bosco E, Galateau‐Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA A Cancer Journal For Clinicians 2019, 69: 402-429. PMID: 31283845, PMCID: PMC8192079, DOI: 10.3322/caac.21572.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalAsbestosAustraliaBiomarkers, TumorCarcinogenesisCombined Modality TherapyDiagnostic ErrorsEuropeGenetic Predisposition to DiseaseGerm-Line MutationGlobal Burden of DiseaseHumansIncidenceInhalation ExposureInternational CooperationMesotheliomaMolecular Targeted TherapyOccupational ExposurePleuraPleural NeoplasmsPneumonectomyPrognosisTumor Suppressor ProteinsUbiquitin ThiolesteraseUnited StatesConceptsNovel systemic treatmentsRole of surgeryKey pathogenic mechanismsAccuracy of diagnosisAggressive managementSystemic treatmentLocal therapyPeritoneal mesotheliomaPleural mesotheliomaMesothelioma incidenceIncidence rateTreatment outcomesProtein 1 mutationImmune responseGermline BRCA1Epidemiological studiesMortality ratePathogenic mechanismsMesotheliomaMesothelioma diagnosisUse of asbestosInadequate treatmentOlder individualsOlder peopleEarly detection
2018
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation
Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical Lung Cancer 2018, 20: e137-e141. PMID: 30553716, DOI: 10.1016/j.cllc.2018.11.003.Peer-Reviewed Original Research
2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2017, 19: 58-64. PMID: 28645632, DOI: 10.1016/j.cllc.2017.05.015.Peer-Reviewed Original ResearchConceptsHigh-risk patientsDisease-free survivalLow-risk patientsAdjuvant chemotherapyNational Comprehensive Cancer Network guidelinesCell lung cancer patientsMolecular profilingEarly-stage NSCLCHigh-risk criteriaLog-rank analysisCell lung cancerHigh-risk designationLung cancer patientsKaplan-Meyer estimatesAdjuvant treatmentNonsquamous NSCLCOccult metastasesStage IAStage NSCLCAdjuvant interventionClinicopathologic characteristicsComplete resectionConsecutive patientsDisease recurrenceNCCN criteria
2016
Lung Cancer Staging and Prognosis
Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treatment And Research 2016, 170: 47-75. PMID: 27535389, DOI: 10.1007/978-3-319-40389-2_3.Peer-Reviewed Original ResearchConceptsTNM stageLung Cancer Lung Cancer Staging ProjectCancer TNM staging systemLung Cancer Staging ProjectSurvival estimatesIndividualized survival estimatesNew immunotherapy drugsStage IA diseaseStage IV diseaseImportant prognostic factorTNM staging systemPoor prognostic indicatorMolecular prognostic markersSignificant survival differenceTumor histologic gradeLung cancer stagingMolecular tumor profilingGenetic tumor analysisIA diseaseTNM groupingsOverall survivalPerformance statusMolecular prognosticationPD-L1Prognostic factorsSignificance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics
Yang D, Woodard G, Zhou C, Wang X, Liu Z, Ye Z, Li K. Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics. Thoracic Cancer 2016, 7: 535-542. PMID: 27766777, PMCID: PMC5130210, DOI: 10.1111/1759-7714.12363.Peer-Reviewed Original ResearchConceptsProgression-free survivalResponse Evaluation CriteriaTumor cavitationPrognostic informationTreatment responseTumor responseTumor densitySignificant differencesPrediction of PFSRadiographic treatment responseAdditional prognostic informationUseful prognostic signCertain radiographic signsPrognostic signTumor diameterLung cancerShort-axis sizeRadiographic signsTumor assessmentPatientsSolid tumorsTumor changesRECIST1.1Imaging characteristicsPFSWhole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas
Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget 2016, 7: 8321-8331. PMID: 26824986, PMCID: PMC4884995, DOI: 10.18632/oncotarget.7032.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternExomeFemaleGenome, HumanHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseHumansImmunoenzyme TechniquesLoss of HeterozygosityLung NeoplasmsMesotheliomaMesothelioma, MalignantMiddle AgedMutationPleural NeoplasmsPrognosisProtein MethyltransferasesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsMalignant pleural mesotheliomaPrimary cancerPleural mesotheliomaGenetic mechanismsDeep sequencingAdditional primary cancersMultiple primary cancersPrimary lung cancerPrimary cancer developmentAllelic lossNew genetic mechanismWhole-exome sequencingDistinct genomic alterationsMPM patientsRare malignancyPerineural invasionPoor prognosisTherapeutic optionsLung cancerLoss of heterozygosityTP53 mutationsCancer developmentPatientsExome sequencingCancer
2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLOS ONE 2015, 10: e0132134. PMID: 26132438, PMCID: PMC4488446, DOI: 10.1371/journal.pone.0132134.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellCell MovementChemotherapy, AdjuvantCombined Modality TherapyCyclophosphamideDeoxycytidineDown-RegulationDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGemcitabineGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLungLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingOrganoplatinum CompoundsPaclitaxelPneumonectomyPrognosisRNA InterferenceRNA, Small InterferingTranscription FactorsVinblastineVinorelbineConceptsLung squamous cell carcinomaSquamous cell carcinomaLung SCC patientsNon-small cell lung cancerLung SCC cellsLung SCC cell linesSCC patientsSCC cell linesAdjuvant chemotherapyCell carcinomaPredictive markerSCC cellsEMX2 expressionImproved overall survivalCurrent staging methodsTissue samplesCell lung cancerNovel prognostic markerAdjacent normal tissuesCell linesOverall survivalSurgical resectionLung cancerPatient outcomesPrognostic marker
2014
Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLow-risk patientsStage IBNCCN criteriaNCCN guidelinesRisk stratificationHigh-risk clinicopathologic featuresEarly-stage NSCLC patientsAdjuvant chemotherapy recommendationsMonths of patientsMolecular risk stratificationCell lung cancerIdentification of patientsSmall cohort studiesMolecular risk assessmentBlinded chart reviewMolecular assaysAdjuvant chemotherapyChemotherapy recommendationsNonsquamous NSCLCStage IAChart reviewCohort studyNSCLC patientsRecurrence outcomes